Newer therapies - DiabetesontheNet

This site is intended for healthcare professionals only

Newer therapies

Filter:

Joint PCDS and ABCD guidance: GLP-1 receptor agonist national shortage

Joint guidance from the PCDS and ABCD to support clinicians in selecting alternative glucose-lowering therapies when GLP-1 RAs are unavailable.

Diabetes Distilled: Renoprotective benefits associated with SGLT2 inhibitor use in real-world studies

Meta-analysis suggests SGLT2 inhibitors are associated with a 46% lower risk of renal failure compared with other diabetes drugs.

Conference news: Highlights from the 83rd Scientific Sessions of the American Diabetes Association

A look at the headlines from a diabetes nursing perspective.

What is health? The importance of patient-centred outcomes

Vinod Patel considers what defines health, what matters to our patients with type 2 diabetes and how to promote this.

Effects of novel glucose-lowering therapies on physical function

A potential benefit of newer diabetes therapies, particularly GLP-1 RAs, in improving physical function in people with type 2 diabetes.

Network meta-analysis of benefits and harms associated with currently available type 2 diabetes drugs

Monumental analysis synthesises current evidence on the benefits and risks associated with currently available diabetes drug classes.

Real-world data demonstrate renoprotective effects of SGLT2 inhibitors

Renoprotective benefits of SGLT2 inhibitors extend to the broader population of people with type 2 diabetes who are treated in routine clinical practice.

Editorial: The growing number of options for lipid lowering

Jane Diggle proposes an opportunity to revisit lipid lowering in patients who cannot tolerate or refuse statin therapy.

Diabetes Distilled: I can see CLEAR-ly now the LDL is down

Bempedoic acid significantly reduces 4-point MACE in statin-intolerant individuals.

Diabetes Distilled: SGLT2 inhibitors – the gift that keeps on giving

Dapagliflozin reduces the need to initiate gout medications in people with heart failure, in this post hoc analysis.

You are what – and when – you eat

New evidence on low-carb diets, ultra-processed foods and time-restricted eating, plus GLP-1 RAs, risk markers and diabetes complications.

GLP-1 RAs and stroke: Meta-analysis

GLP-1 RAs are associated with a significantly lower risk of cerebrovascular events compared with placebo and active comparators.

Editorial: Keeping abreast of the ever-changing landscape of diabetes care

Jane Diggle reflects on an array of recent developments in diabetes care and how they might impact on practice.

How to use GLP-1 receptor agonist therapy safely and effectively

The latest guidance and practical tips on the safe use of glucagon-like peptide-1 receptor agonists.

Interactive case study: Heart failure and type 2 diabetes

The different categories of heart failure and the latest recommended therapies, and which diabetes drugs should be avoided or used with caution.

Diabetes Distilled: More evidence that SGLT2 inhibitors slow CKD progression. Are we optimising care?

Empagliflozin's renoprotective effects extend to people with eGFR levels as low as 20 at baseline.

Low-dose empagliflozin as an adjunct to hybrid closed-loop therapy

Low-dose empagliflozin increases time in range by ~10% compared with placebo in people using closed-loop therapy.

Journal club: Reducing health inequality – a simple step for practising healthcare professionals to take

Recent key papers on type 2 diabetes. What can we specially do in clinical practice to address health inequalities, both pragmatically and practically?

Resources

For the latest news and articles

Sign up to all DiabetesontheNet journals

Follow us for all the latest news and updates in diabetes.

Resources

Journals

Useful information

© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom

;